一分钟看懂
这是一项关于肺癌的I 期研究，登记的药物或干预包括BI 764532；Carboplatin；Etoposide；Atezolizumab，当前状态为研究进行中，已停止招募。登记地点显示中国Orlando、Atlanta、Brussels、Kortrijk等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BI 764532；Carboplatin；Etoposide；Atezolizumab · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Orlando Health Cancer Institute · Orlando
- Emory University · Atlanta
- Cliniques Universitaires Saint-Luc · Brussels
- AZ Groeninge · Kortrijk
- INS Bergonie · Bordeaux
- Hopital Louis Pradel · Bron
- HOP Civil · Strasbourg
- Institut Gustave Roussy · Villejuif
- Universitätsklinikum Gießen und Marburg GmbH · Giessen
- Saitama Medical University International Medical Center · Saitama, Hidaka
- Hamamatsu University Hospital · Shizuoka, Hamamatsu
- National Cancer Center Hospital · Tokyo, Chuo-ku
- Japanese Foundation for Cancer Research · Tokyo, Koto-ku
- Medical University Gdansk · Gdansk
- Polish Mother's Memorial Hospital - Research Institute · Lodz
- Med Polonia Sp. z o.o · Poznan
- Hospital Universitario Ramon Y Cajal · Madrid
- Fundación Jiménez Díaz · Madrid
- Hospital Universitario Virgen De La Macarena · Seville
- Instituto Valenciano de Oncología · Valencia
- University Hospital of Lausanne · Lausanne
公开的入选条件
- * Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the informed consent form (ICF)
- * Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
- * Histologically or cytologically confirmed extensive-stage small cell lung carcinoma (ES-SCLC)
- * Availability of archival tumour tissue
- * Patients must be eligible for platinum+etoposide+anti-Programmed Cell Death Ligand 1 (PD-L1) regimen as first line standard of care (SoC) treatment:
- In Part A, patients must be eligible to receive carboplatin + etoposide + atezolizumab
- In Part B, patients must be eligible to receive etoposide, carboplatin or cisplatin, and atezolizumab or durvalumab
- * No prior systemic treatment for ES-SCLC
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06077500；登记信息更新于 2026-09-16。